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Purpose. Damage to corneal nerve fibers has been demonstrated in people with type 2 diabetes mellitus (T2DM) that further
progresses with increasing severity of diabetic peripheral neuropathy. However, the role of C-peptide in corneal nerve damage
has not been reported in T2DM. The present study investigated the relationship of fasting C-peptide levels with corneal
neuropathy evaluated by corneal confocal microscopy (CCM) in patients with T2DM. Methods. 160 T2DM patients (72
females) aged 34-78 with duration ranging from 0 to 40 years underwent CCM to measure corneal nerve fiber length (CNFL),
corneal nerve fiber density (CNFD), and corneal nerve branch density (CNBD). Pearson correlation analysis and multiple linear
regression analysis were used to explore the association of fasting C-peptide levels with corneal nerve parameters. Partial
correlation analysis (adjusted for age and gender) was also conducted to analyze the correlation of metabolic indexes with these
three corneal nerve parameters. The relationship between fasting C-peptide levels and duration of diabetes was also explored by
Pearson correlation analysis. Results. With an increase in fasting C-peptide levels, the values of CNFL, CNFD, and CNBD also
showed a corresponding trend for an increase. Partial correlation analysis revealed that fasting C-peptide levels were positively
associated with CNFL (r = 0:245, P = 0:002), CNFD (r = 0:180, P = 0:024), and CNBD (r = 0:214, P = 0:008) after adjusting for
age and gender. Using multiple linear regression analysis, fasting C-peptide levels were also closely associated with CNFL
(P = 0:047) and CNBD (P = 0:038) after multiple adjustments. However, this association disappeared after further adjusting for
duration of diabetes. Further analysis indicated that fasting C-peptide levels declined with duration of diabetes (r = −0:267, P =
0:001). Conclusions. C-peptide was closely associated with corneal neuropathy and disease duration in T2DM. C-peptide levels
might be both an indicator of beta-cell function and a marker of disease severity (such as diabetic corneal neuropathy) and
duration.
1. Introduction
The prevalence of diabetic peripheral neuropathy (DPN) was
estimated 8-45% in patients with type 2 diabetes mellitus
(T2DM) [1]. DPN could lead to distressing neuropathic pain,
insensitivity to trauma leading to foot ulceration, and auto-
nomic neuropathy affecting several systems, all resulting in
significant morbidity and increased mortality [2, 3]. Injury
of the small nerve fibers is probably the earliest manifestation
of DPN [4, 5]. However, DPN is often diagnosed based on
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neurological and electrophysiological testing of large nerve
fibers in clinical practice, which results in delayed diagnosis
[6]. At present, apart from tight glycemic control in T1DM,
there are no effective treatments that can reverse or prevent
the progression of DPN [7]. Many compounds that showed
promising results in animal models of DPN have not trans-
lated to human clinical trials. This has in part been due to
the lack of sensitive early markers/measures of DPN. There-
fore, the development of a reliable method of detecting early
damage of small nerve fibers and the search for potential pro-
tective factors of these small nerve fibers would be of great
value.
Corneal confocal microscopy (CCM) is an objective and
noninvasive imaging technique that has been validated to
quantify corneal small nerve fibers [8]. Corneal nerve loss
has been found in recently diagnosed people with T2DM
[9] and is strongly associated with the severity of DPN [10].
Moreover, corneal nerve regeneration on CCM has been
demonstrated in T1DM patients following simultaneous
pancreas and kidney transplantation (SPK) [11, 12]. Addi-
tionally, the predictive validity of CCM for DPN has been
reported in a prospective study, with a baseline corneal nerve
fiber length (CNFL) of <14.9mm/mm2 being the strongest
predictor [13]. Therefore, CCM is not only a powerful diag-
nostic tool for the early detection of DPN but also an effective
evaluation parameter for the therapeutic effect of interven-
tions in DPN.
The protective effect of C-peptide on DPN in T1DM had
been confirmed by various studies [14–17]. However, the
relationship between C-peptide and DPN in T2DM remains
unclear. Several studies have found that C-peptide had a pro-
tective effect on DPN [18–21], while others have not
observed such an effect [22] or indeed observed a contrary
result [23]. To our knowledge, no study investigated the rela-
tionship of C-peptide levels with corneal nerve loss/damage
in T2DM.
The present study investigated the relationship of fasting
C-peptide levels with corneal neuropathy evaluated by CCM
in patients with T2DM.
2. Methods
2.1. Study Population. We recruited 160 T2DM patients (72
females) aged 34-78 with duration ranging from 0 to 40 years
at Qilu Hospital of Shandong University fromMarch 2016 to
December 2019. Exclusion criteria were as follows: history of
(1) acute myocardial infarction, acute cerebral infarction,
cerebral hemorrhage, tumor, infectious disease, severe
hepatic, or renal disease; (2) corneal trauma, ocular disease,
or systemic disease that might affect the cornea; (3) cigarette
smoking and excessive alcohol consumption; and (4) taking
any of the following medications: insulin secretagogues and
statins. Diabetes was diagnosed based on the 2006 World
Health Organization (WHO) criteria [24]. The study proto-
col adhered to the provisions of the Helsinki Declaration
and was approved by the ethics committee of Qilu Hospital.
All subjects signed informed consent to participate in the
study.
2.2. Data Collection. Basic demographic information was col-
lected by the data collection system of Qilu Hospital and
structured history. These included age, gender, BMI, blood
pressure (BP), duration of diabetes, history of smoking and
alcohol consumption, previous medical history, and medica-
tion history. Antidiabetic medications were classified as fol-
lows: insulin, metformin, alpha glucosidase inhibitor, and
others (thiazolidinedione, dipeptidyl peptidase-4 inhibitors,
and others). After fasting for at least 10 hours, venous blood
was collected for the measurement of glucose, HbA1c, tri-
glycerides, total cholesterol (TC), and creatinine by use of
an automatic analyzer (ARCHITECT ci16200 Integrated
System, Abbott, USA). Plasma C-peptide levels were mea-
sured at the hospital laboratory using the Cobas e 602 ana-
lyzer (Roche Diagnostics, Mannheim, Germany). The
calibration of the assay ranged from 0.06 to 6.2 ng/mL.
Patients on long-acting insulin treatment stopped insulin
injections 24 hours before blood collection. All subjects
underwent CCM examination using the Heidelberg Retina
Tomograph Rostock Cornea Module (HRT-III, Heidelberg,
Germany) according to a standard procedure [12]. Three,
nonoverlapping images from the center of the cornea were
selected for quantification from each eye of each person. Data
acquired from these images were averaged for each eye, and
the mean values of both eyes were used for analysis. Three
corneal nerve parameters were measured: CNFL was calcu-
lated in mm/mm2 as the total length of all nerve fibers and
branches; CNFD indicated the total number of major nerves
per mm2; CNBD indicated the number of branches emanat-
ing from the major nerve trunks per mm2.
2.3. Statistical Analysis. Statistical analyses were performed
using SPSS 22.0 software (SPSS Inc., Chicago, USA). Firstly,
the data were assessed for normality using the Kolmogorov-
Smirnov test. Data were expressed as the means ± SD or
median (interquartile range) or number (%). The differences
between groups were compared by one-way ANOVA (LSD)
(continuous data with normal distribution) or Mann–Whit-
ney U test (continuous data with skewed distribution) or
chi-square test (categorical data). The values of the three cor-
neal nerve parameters were expressed as box and whiskers
with 5-95 percentiles in Figure 1. Pearson correlation analysis
and multiple linear regression analysis were used to explore
the association of fasting C-peptide levels with three corneal
nerve parameters. Partial correlation analysis (adjusted for
age and gender) was conducted to analyze the correlation
of metabolic indexes with three corneal nerve parameters.
The relationship between fasting C-peptide levels and dura-
tion of diabetes was also explored by Pearson correlation
analysis. P < 0:05 was considered statistically significant.
3. Results
3.1. General Characteristics of Participants. All subjects were
divided into four groups based on the quartiles of fasting C-
peptide levels. As shown in Table 1, with increasing fasting
C-peptide levels, BMI also increased. Patients with the lowest
fasting C-peptide levels presented the highest TC levels.
Moreover, patients with higher fasting C-peptide levels had
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a shorter duration of diabetes. The choice of hypoglycemic
treatment was also different between groups. We then com-
pared the differences of CNFL, CNFD, and CNBD between
groups (Table 1 and Figure 1). Overall, with the increase of
fasting C-peptide levels, the values of CNFL, CNFD, and
CNBD also showed an increasing trend.
3.2. The Correlation of Fasting C-peptide Levels andMetabolic
Indexes with Corneal Nerve Parameters. In order to assess the
correlation of fasting C-peptide levels with corneal nerve
parameters, we firstly conducted a Pearson correlation anal-
ysis and observed that fasting C-peptide levels were positively
associated with CNFL, CNFD, and CNBD (Figure 2). Then,
we carried out a partial correlation analysis to further explore
the correlation of fasting C-peptide levels and other meta-
bolic indexes with corneal nerve parameters. As shown in
Table 2, after adjusting for age and gender, fasting C-
peptide levels were also positively associated with CNFL,
CNFD, and CNBD. Moreover, a negative correlation of
HbA1c, duration of diabetes, and TC with CNFL, but not
with CNFD and CNBD, was observed.
3.3. Multiple Linear Regression Analysis of Fasting C-peptide
Levels with Corneal Nerve Parameters.Multiple linear regres-
sion analysis was then used to further investigate the correla-
tion of fasting C-peptide levels with corneal nerve parameters
in different models. As shown in Table 3, before adjustment,
fasting C-peptide levels were closely associated with CNFL,
CNFD, and CNBD. Then, we added age, gender, BMI, SBP,
HbA1c, triglyceride, TC, eGFR, insulin treatment, metfor-
min, alpha glucosidase inhibitor, and other antidiabetic med-
ications into the model. Fasting C-peptide levels were also
closely associated with CNFL and CNBD. As DPN was
closely tied to the duration of disease, we further put duration
of diabetes into the model (model 3). Unfortunately, fasting
C-peptide levels no longer showed a close association with
corneal nerve parameters. Finally, we assessed the relation-
ship between fasting C-peptide levels and duration of diabe-
tes. As shown in Figure 3, fasting C-peptide levels declined
with duration of diabetes.
4. Discussion
DPN was one of the most common microvascular complica-
tions in diabetes. DPN could affect both large and small nerve
fibers, and small nerve fiber damage was an earlier parameter
of DPN [4, 5]. Therefore, the search for an objective and sen-
sitive assessment method for small nerve fiber damage is very
important for the early diagnosis and prevention of DPN.


































































Figure 1: Differences of CNFL, CNFD, and CNBD between groups based on the quartiles of fasting C-peptide levels. ∗P < 0:05 and
∗∗
P < 0:01.
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nerve fiber damage [25]. However, its invasive feature limits
its routine use in clinical practice [26]. Recently, CCM, an
objective and noninvasive imaging technique, has been
developed as an alternate measure of DPN and has been dis-
cussed in detail in several recent reviews [27, 28]. Corneal
nerve assessment could be used not only for the early diagno-
sis of DPN but also for the evaluation of the efficacy of an
intervention. There is now a wealth of studies that confirm
the utility of corneal parameters including CNFL, CNFD,
and CNBD that are able to distinguish patients with and
without DPN [27].
At present, there are no universally accepted disease-
modifying treatments that can reverse or prevent progression
of DPN [7]. Therefore, the identification of potential protec-
tive factors for DPN would be very useful in tackling the dis-
ease. The protective role of C-peptide for DPN in T1DM has
been well recognized [14–17]. However, this benefit remains
unclear in T2DM. Recently, Zaharia et al. [29] confirmed an
association between a phenotype of severe insulin-deficient
diabetes (not autoimmune) and diabetic sensorimotor poly-
neuropathy in the newly diagnosed population of the Ger-
man Diabetes Study, indicating the possible protective role
of C-peptide (or insulin) on DPN. Actually, most studies
conducted in T2DM suggested a protective effect of C-
peptide on DPN [18–21]. However, Sari and Balci [22] dem-
onstrated that there was no relationship between C-peptide
and sensory neuropathy. Gottsäter et al. [23] even found that
patients with parasympathetic neuropathy presented with
higher fasting C-peptide levels. The conflicting results might
be partly ascribed to the different assessment methods of
DPN in these studies. Therefore, the relationship between
C-peptide and DPN in carefully designed studies may pro-
vide much needed clarification.
Since CCM had been widely used as a sensitive measure
of DPN and no study had been done to explore the associa-
tion of C-peptide with corneal nerve damage in patients with
T2DM, we conducted this cross-sectional study. We found
that with an increase in fasting C-peptide levels, CNFL,
CNFD, and CNBD also showed a corresponding increase.
Both Pearson correlation analysis and partial correlation
analysis showed that fasting C-peptide levels were positively
associated with CNFL, CNFD, and CNBD. Even after adjust-
ing for age, gender, BMI, SBP, HbA1c, triglyceride, TC,
eGFR, insulin treatment, metformin, alpha glucosidase
inhibitor, and other antidiabetic medications in a multiple
linear regression analysis, this positive correlation also per-
sisted. All these results indicate a possible protective effect
of fasting C-peptide on corneal nerves in T2DM. The molec-
ular mechanisms involved in the protective effect of C-
peptide on neuropathy mainly come from animal studies in
Table 1: Characteristics of participants by fasting C-peptide quartiles.
Characteristics Quartile 1 (n = 40) Quartile 2 (n = 40) Quartile 3 (n = 40) Quartile 4 (n = 40) P valuea
Female (n (%)) 21 (52.5%) 20 (50.0%) 14 (35.0%) 17 (42.5%) 0.387
Age (years) 56:73 ± 9:11 57:98 ± 7:12 56:78 ± 8:92 55:73 ± 9:86 0.727
BMI (kg/m2) 23:94 ± 3:78 25:94 ± 3:43b 26:65 ± 3:44b 27:77 ± 4:29bc <0.001
Systolic BP (mmHg) 135:20 ± 21:04 142:25 ± 22:35 143:50 ± 17:19 141:30 ± 21:15 0.280
Diastolic BP (mmHg) 78:30 ± 13:47 80:23 ± 13:61 81:63 ± 11:94 82:13 ± 12:52 0.550
FBG (mmol/L) 8:22 ± 2:40 8:27 ± 2:06 8:09 ± 2:76 7:81 ± 2:25 0.824
HbA1c (%) 8:67 ± 1:88 8:14 ± 1:75 8:44 ± 1:83 7:71 ± 1:59b 0.092
Fasting C-peptide (ng/mL) 0:68 ± 0:23 1:23 ± 0:15b 1:75 ± 0:17bc 2:77 ± 0:73bcd <0.001
Duration of diabetes (years) 12.00 (7.00-16.75) 12.50 (8.00-17.00) 10.00 (4.25-16.00) 7.00 (2.63-10.00)bc 0.002
Triglyceride (mmol/L) 1.43 (0.94-2.27) 1.41 (0.98-2.47) 1.31 (0.97-2.55) 1.37 (1.05-2.38) 0.906
TC (mmol/L) 5:24 ± 1:21 4:45 ± 1:26b 4:43 ± 0:97b 4:63 ± 1:11b 0.006
Creatinine (μmol/L) 63:60 ± 14:11 63:30 ± 13:04 71:78 ± 33:05 63:41 ± 21:81 0.234
eGFR (mL/min/1.73m2) 96:92 ± 13:67 97:35 ± 13:29 95:01 ± 20:15 102:04 ± 20:73 0.316
Insulin treatment (n (%)) 34 (85.0%) 24 (60.0%)b 20 (50.0%)b 13 (32.5%)bc <0.001
Long-acting insulin analogues (n (%)) 31 (77.5%) 23 (57.5%)b 16 (40.0%)b 9 (22.5%)bc <0.001
Metformin (n (%)) 25 (62.5%) 33 (82.5%) 33 (82.5%) 29 (72.5%) 0.118
Alpha glucosidase inhibitor (n (%)) 13 (32.5%) 16 (40.0%) 18 (45.0%) 23 (57.5%)b 0.003
Other antidiabetic medications (n (%)) 3 (7.5%) 2 (5.0%) 10 (25.0%)bc 4 (10.0%) 0.026
CNFL (mm/mm2) 13:94 ± 4:16 13:38 ± 3:89 16:38 ± 2:98bc 16:39 ± 3:60bc <0.001
CNFD (number/mm2) 20:58 ± 9:90 19:29 ± 7:03 23:60 ± 7:63c 24:16 ± 7:23bc 0.019
CNBD (number/mm2) 33:19 ± 26:06 28:01 ± 18:70 40:20 ± 18:42c 44:75 ± 22:58bc 0.004
The data are expressed as the means ± SD or median (interquartile range). BMI: body mass index; BP: blood pressure; FBG: fasting blood glucose; TC: total
cholesterol; eGFR: estimated glomerular filtration rate; CNFL: corneal nerve fiber length; CNFD: corneal nerve fiber density; CNBD: corneal nerve branch
density. aDifference between four groups; bP < 0:05 compared with Quartile 1 group; cP < 0:05 compared with Quartile 2 group; dP < 0:05 compared with
Quartile 3 group.
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T1DM [30]. In BB/Wor rats, C-peptide administration pre-
vented the development of nerve conduction velocity
(NCV) deficits [31]. Further study found that administration
of C-peptide in physiological concentrations corrected the
endoneurial perfusion deficit caused by diabetes via a NO-
sensitive mechanism [32]. Moreover, C-peptide in physiolog-
ical concentrations could partially correct the reduction of
Na+-, K+-ATPase activity induced by diabetes thereby reduc-
ing the observed paranodal swelling through reduced Na+
retention [31, 33].
Corneal nerve damage is not only associated with DPN
but is also an important risk factor for diabetic neurotrophic
keratopathy, a manifestation of ocular surface dysfunction
[34]. Corneal nerves provide trophic support to the corneal
epithelial cells by secreting mediators and epithelial cells,
and these in turn provide trophic support to corneal neurons
by releasing growth factors [35]. However, diabetes reduces
the concentrations of these mediators, leading to damage of
epithelial integrity and further neuronal loss, eventually
resulting in diabetic neurotrophic keratopathy [36]. We
found the positive association of C-peptide with corneal
nerve parameters in T2DM patients. The role of C-peptide
in diabetic neurotrophic keratopathy remains to be further
studied. As DPN was closely tied to increasing duration of
diabetes [37] and hence decline in β-cell function, there is a
clear rationale to study the relationships between diabetes
duration, C-peptide, and the extent of corneal nerve damage.
First, the partial correlation analysis revealed that duration of
diabetes is negatively associated with CNFL, which is consis-
tent with previous studies [38]. Then, we put duration of dia-
betes into the model of multiple linear regression analysis to
see the relationship between fasting C-peptide levels and cor-
neal nerve parameters. However, a clear relationship between
fasting C-peptide levels and corneal nerve parameters was no
longer observed, indicating that diabetes duration might play
a role in mediating the relationship between C-peptide and

































































Figure 2: Correlation of fasting C-peptide levels with CNFL, CNFD, and CNBD.
Table 2: Partial correlation analysis of metabolic indexes with












BMI 0.128 0.108 0.067 0.405 0.033 0.689
Systolic BP -0.040 0.614 -0.057 0.480 0.038 0.645
Diastolic BP -0.009 0.911 -0.004 0.960 0.027 0.743
FBG -0.153 0.055 -0.156 0.050 -0.114 0.161
HbA1c -0.211 0.008 -0.117 0.142 -0.143 0.077
Duration of
diabetes
-0.210 0.008 -0.107 0.181 -0.090 0.269
Triglyceride 0.045 0.575 0.038 0.640 0.036 0.661
TC -0.167 0.036 -0.152 0.058 -0.153 0.060
Creatinine -0.014 0.866 0.007 0.929 0.026 0.752
eGFR -0.009 0.908 0.009 0.915 -0.051 0.535
Fasting C-peptide 0.245 0.002 0.180 0.024 0.214 0.008
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C-peptide levels declined with duration of diabetes. All these
data suggested that fasting C-peptide levels might be both an
indicator of beta-cell function and a marker of disease sever-
ity (such as diabetic corneal neuropathy) and duration.
Some limitations of this study should be noted. First, as
this is a cross-sectional study, it is not possible to determine
causality between fasting C-peptide levels and corneal nerve
damage. Second, we only included Chinese with T2DM in
this study and the results need to be confirmed in patients
with other ethnicities and patients with T1DM. Third, we
did not evaluate the presence of diabetic peripheral and auto-
nomic neuropathy in the population as it was closely associ-
ated with the CCM alterations. The choice of a very sensitive
testing (such as CCM) might seem to be undermined by the
long disease duration of the study population and the lack of
a comparison with standard testing modalities for diabetic
polyneuropathy. Fourth, we did not exclude patients who
were receiving insulin therapy as insulin administration
might affect fasting C-peptide levels, especially the use of
long-acting analogues. However, to exclude the effect of insu-
lin therapy on results, insulin injections were stopped 24
hours before blood collection for patients on long-acting
insulin treatment and we had adjusted for patients’ antidia-
betic medication (including insulin therapy) in models of
Table 3. Lastly, some confounding factors (such as inflamma-
tory factors) that might affect the levels of fasting C-peptide
or DPN may not have been adjusted for. However, in order
to reduce the influence of such factors as far as possible, we
had a strict exclusion criterion as described in Methods.
In conclusion, we found that fasting C-peptide levels
were positively associated with CNFL, CNFD, and CNBD
and negatively correlated with duration of diabetes. Fasting
C-peptide levels might be both an indicator of beta-cell func-
tion and a marker of disease severity (such as diabetic corneal
neuropathy) and duration. Further prospective and interven-
tion studies are now required to investigate the role of C-
peptide in corneal neuropathy and T2DM DPN.
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